Warning: fsockopen() [function.fsockopen]: unable to connect to (Connection refused) in /home/content/67/4046467/html/administrator/components/com_joomlastats/count.classes.php on line 1038

Warning: fsockopen() [function.fsockopen]: unable to connect to (Connection refused) in /home/content/67/4046467/html/administrator/components/com_joomlastats/count.classes.php on line 1038

Warning: fsockopen() [function.fsockopen]: unable to connect to (Connection refused) in /home/content/67/4046467/html/administrator/components/com_joomlastats/count.classes.php on line 1038
Home Services Patient Registries

Patient Registries


Patient Registries offer unique and creative solutions in a pre and post launch environment.  Used for the collection of observational, epidemiologic, actual use, health outcomes, economic outcomes data.  Utilizing web, phone, email, paper mail, strategies, our Registry services provide a fast and one stop solution.


Randomized Clinical Trials are not the best instruments for many research questions posed for healthcare products, drugs & devices.  They often, and by design, driven by atypical use patterns, narrowly defined populations, encounter unusual medical practice.  These are also analyzed by methods not well suited for real world use.  In the simplest form, these trials give minimal if any insight into the who/why/how of product use.  Generally, these study populations are small, and not at all well suited for outcomes analysis.


When developing a patient registry program, careful design will yield extremely useful outcomes data.  Properly designed, prospective studies, apprpriate real-world selection criteria, *observational* trials are a hallmark of the most useful registry programs. 


Points to remember;

  • Efficacy trial vs. Effectiveness observational study
  • Clinical or Cost Effectiveness
  • Measure or Monitor Safety
  • Real World Healthcare Observational Parameters


We'll begin designing a registry study by first understanding the product in a comprehensive fashion.  Understanding if and how a patient registry will offer outcomes data to the product.  We need to look at the patient outcomes variables, the defining questions for those variables, the natural history of the disease, specifics on patient care and disease management.  The program then turns to a detailed examination of registry purpose, observational metrics to accomplish that purpose, carefully constructing the instruments to that goal.


Designing a program is only part of the challenge.  Implementing a patient registry is not simpy another clinical trial, or a phase IV trial.  Treated as such, will not prodcue the same results, nor yield the most useful data for the sponsor.


Synergy Research Patient Registry Services


Recently the Agency for Healthcare Research and Quality, AHRQ, released the 2nd edition of:  "REGISTRIES FOR EVALUATING PATIENT OUTCOMES:  A USER'S GUIDE"




 . . loading . . .




News & Events

  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access Cell Therapeutics... Read more>>
  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
  • Proximagen Signs Deal With Upsher-Smith Proximagen Neuroscience plc, a biotechnology company... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>